What it is
Orforglipron is not a peptide. It is a small-molecule, non-peptide agonist of the glucagon-like peptide-1 (GLP-1) receptor, developed under the code LY3502970 (also OWL833) and designed for once-daily oral dosing. It is included here because it acts on the same receptor as peptide drugs such as semaglutide and tirzepatide, and its trials are usually read alongside theirs. Eli Lilly tested it in phase 2 and phase 3 trials in obesity and type 2 diabetes before its 2026 FDA approval.
Mechanism of action
Orforglipron activates the GLP-1 receptor, the receptor used by the gut hormone GLP-1, whose activation raises glucose-dependent insulin secretion, lowers glucagon release and slows gastric emptying, with receptors in appetite-regulating brain regions thought to account for reduced food intake. Kawai et al. (2020) solved a cryo-EM structure of the compound bound to the active receptor. It sits in a distinct pocket in the upper part of the receptor's helical bundle, contacting the extracellular domain, extracellular loop 2 and transmembrane helices 1, 2, 3 and 7. In signaling assays it behaved as a partial agonist biased toward G protein activation over beta-arrestin recruitment. Its binding depends on a tryptophan (Trp33) found in primate receptors, so the authors tested it in mice carrying the human receptor, where oral dosing lowered glucose, and in nonhuman primates, where it increased insulin secretion and reduced food intake. Whether the signaling bias matters clinically is not established.
What it’s most studied for
Orforglipron is most studied for body weight reduction and glycemic control. Its development program asked whether a pill that does not need to be a peptide could produce results in the range seen with injectable GLP-1 receptor agonists. Phase 2 dose-ranging trials in adults with obesity (Wharton et al. 2023) and in type 2 diabetes (Frias et al. 2023) were followed by phase 3 trials, including ACHIEVE-1 in early type 2 diabetes and ATTAIN-1 in obesity without diabetes, both published in 2025. ATTAIN-1 results were cited at the 2026 approval for chronic weight management.
Notable findings
Each finding carries the species or population it was observed in and the dose that study used. Doses are reported as research context, exactly as published. They are not guidance.
Weight reduction over 72 weeks (ATTAIN-1)
Wharton et al. (2025) randomized 3,127 adults with obesity, or overweight with a weight-related condition, and without diabetes, in nine countries, to orforglipron or placebo alongside diet and physical activity. Counting all participants regardless of adherence (the treatment-regimen estimand), mean weight change at 72 weeks was −7.5%, −8.4% and −11.2% with 6, 12 and 36 mg versus −2.1% with placebo. Lilly's efficacy estimand, which estimates the effect had everyone stayed on treatment, was −12.4% at 36 mg versus −0.9% with placebo. Adverse events, mostly gastrointestinal, led to discontinuation in 5.3% to 10.3% of orforglipron groups versus 2.7% with placebo, and no hepatic safety signal was seen.
- Dose studied
- Orforglipron 6, 12 or 36 mg orally once daily, adults without diabetes, 72 weeks
[5] Wharton S et al. · 2025 · PMID 40960239 ↗
Early type 2 diabetes (ACHIEVE-1)
Rosenstock et al. (2025) enrolled 559 adults with type 2 diabetes managed with diet and exercise alone, an HbA1c of 7.0% to 9.5% (mean 8.0%) and a BMI of at least 23. In the published analysis, HbA1c fell by 1.24, 1.47 and 1.48 percentage points with 3, 12 and 36 mg versus 0.41 with placebo at week 40, and body weight fell 4.5% to 7.6% versus 1.7%. Lilly's efficacy-estimand figures were HbA1c reductions of 1.3 to 1.6 points and 7.9% weight loss at 36 mg. Adverse events, mainly gastrointestinal, led to discontinuation in 4.4% to 7.8% of orforglipron groups versus 1.4% with placebo.
- Dose studied
- Orforglipron 3, 12 or 36 mg orally once daily, adults with type 2 diabetes, 40 weeks
[4] Rosenstock J et al. · 2025 · PMID 40544435 (NCT05971940) ↗
Phase 2 dose-ranging trial in obesity
Wharton et al. (2023) randomized 272 adults with obesity or overweight and without diabetes to one of four orforglipron doses or placebo. At the primary week-26 time point, mean weight change ranged from −8.6% to −12.6% across doses versus −2.0% with placebo; by week 36 it ranged from −9.4% to −14.7% versus −2.3%, and 46% to 75% of orforglipron participants had lost at least 10% of body weight, versus 9% on placebo. Gastrointestinal events were mostly mild to moderate, and adverse events led 10% to 17% of orforglipron participants to stop treatment.
- Dose studied
- Orforglipron 12, 24, 36 or 45 mg orally once daily, adults, 36 weeks
[2] Wharton S et al. · 2023 · DOI 10.1056/NEJMoa2302392 (NCT05051579) ↗
Phase 2 trial in type 2 diabetes
Frias et al. (2023) randomized 383 adults with type 2 diabetes at 45 centers in the USA, Hungary, Poland and Slovakia to orforglipron, placebo, or weekly injectable dulaglutide 1.5 mg. At week 26, the placebo-adjusted change in HbA1c ranged from −0.77 percentage points at 3 mg to −1.67 at 45 mg, versus −0.67 with dulaglutide, and placebo-adjusted weight change ranged from −1.6 kg to −7.9 kg, versus −1.4 kg with dulaglutide. Treatment-emergent adverse events occurred in 61.8% to 88.9% of orforglipron groups versus 56.0% with dulaglutide, most of them mild to moderate gastrointestinal events.
- Dose studied
- Orforglipron once daily at doses from 3 mg to 45 mg, orally, adults with type 2 diabetes, 26 weeks; comparator dulaglutide 1.5 mg once weekly, subcutaneous
[3] Frias JP et al. · 2023 · PMID 37369232 ↗
Study quality
The evidence for orforglipron is strong: two published phase 3 randomized, double-blind, placebo-controlled trials in humans (3,127 and 559 participants), two phase 2 dose-ranging trials, and FDA approval for chronic weight management in 2026. The limitations are worth stating plainly. All four trials were sponsored by Eli Lilly. Weight results differ by analysis method: in ATTAIN-1 the top dose produced −11.2% counting everyone randomized and −12.4% under the efficacy estimand, so headline figures should be read with the estimand in mind. These trials measured weight and glucose over 26 to 72 weeks, not cardiovascular events or mortality. Gastrointestinal adverse events were the most common safety finding and drove most discontinuations (5.3% to 10.3% versus 2.7% on placebo in ATTAIN-1). Labeling lists warnings for thyroid tumors, pancreatitis, gallbladder disease, hypoglycemia, kidney problems from dehydration and hypersensitivity. The mechanism work rests on cryo-EM structures, humanized mice and nonhuman primates.
References
- 1Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist. Proceedings of the National Academy of Sciences of the United States of America. PMID 33177239
- 2Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. New England Journal of Medicine. DOI 10.1056/NEJMoa2302392 (NCT05051579)
- 3
- 4Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes. New England Journal of Medicine. PMID 40544435 (NCT05971940)
- 5Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. PMID 40960239
Free guide
Want more than the summary?
Get our free research guide, or tell us about your practice and we’ll get back to you.